Evaluation of the therapeutic effect of molnopiravir for patients with Quid 19

Phase 3

Recruiting

• Conditions: covid-19.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20150107020592N31
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patient over 18 years
With moderate Covid 19 who does not need to be hospitalized.

Exclusion Criteria

Patients with critical covid 19
Gastrointestinal ulcer or inability to swallow oral medication
Thrombocytopenia (platelets less than 100 thousand)
Liver enzymes more than 3 times normal
GFR <30 or require dialysis
Bradycardia (HR <50)
Patient dissatisfaction to enter the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improve oxygenation. Timepoint: 0,1,2,3,5,7 after treatment with Molnopiravir. Method of measurement: pulse oximeter.;Improve ct scan. Timepoint: Five days after starting treatment with mulnopiravir. Method of measurement: CT scan unit.